Ali Eatemadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ali Eatemadi has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Babak Negahdari
Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
9 shared publications Hadis Daraee
B Department of Medical Biotechnology , School of advanced Technologies in Medicine, Tehran University of Medical Sciences , Tehran , Iran
6 shared publicationsMehrdad Namdari
Department of Cardiology, Lorestan University of Medical Sciences, Khoramabad, Iran
4 shared publicationsAbolfazl Akbarzadeh
A Drug Applied Research Center, Tabriz University of Medical Sciences , Tabriz , Iran
3 shared publications- Nosratollah Zarghami
Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
3 shared publications - Mohammad Kouhi
Department of Physics, Tabriz Branch, Islamic Azad University, Tabriz, Iran
2 shared publications
Latest Publications
- 1 April 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 88, 1046-1053
Stem cell, biomaterials and growth factors therapy for hepatocellular carcinoma
- 1 April 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 88, 1046-1053
Stem cell, biomaterials and growth factors therapy for hepatocellular carcinoma
- 29 March 2017
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 46 (1) , 26-32
Diabetic ulcer regeneration: stem cells, biomaterials, growth factors
The impairment of ulcer wound healing in diabetic patients is a vital clinical problem affecting millions of patients. Several clinical and basic science studies have demonstrated that stem cell therapy, to be effective in healing diabetic ulcer. Furthermore, these ulcer wounds may be healed from molecular maneuvering of growth factors to improve microcirculation within the ulcer wound. In addition, ulcer wound dressings may be employed as medicated systems, through the delivery of drugs, growth factors, peptides and stem cells. These dressing materials can include natural, modified and synthetic polymers, as well as their mixtures or combinations. This review paper will give a summary of some of the recent advances on the application of stem cells, biomaterials and growth factors in the treatment of diabetic ulcer wound.
- 29 March 2017
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 46 (1) , 26-32
Diabetic ulcer regeneration: stem cells, biomaterials, growth factors
The impairment of ulcer wound healing in diabetic patients is a vital clinical problem affecting millions of patients. Several clinical and basic science studies have demonstrated that stem cell therapy, to be effective in healing diabetic ulcer. Furthermore, these ulcer wounds may be healed from molecular maneuvering of growth factors to improve microcirculation within the ulcer wound. In addition, ulcer wound dressings may be employed as medicated systems, through the delivery of drugs, growth factors, peptides and stem cells. These dressing materials can include natural, modified and synthetic polymers, as well as their mixtures or combinations. This review paper will give a summary of some of the recent advances on the application of stem cells, biomaterials and growth factors in the treatment of diabetic ulcer wound.
- 24 March 2017
- Published by Institution of Engineering and Technology (IET) in IET Nanobiotechnology
- Vol. 11 (5) , 493-500
Paediatric nanofibrous bioprosthetic heart valve
The search for an optimal aortic valve implant with durability, calcification resistance, excellent haemodynamic parameters and ability to withstand mechanical loading is yet to be met. Thus, there has been struggled to fabricate bio‐prosthetics heart valve using bioengineering. The consequential product must be resilient with suitable mechanical features, biocompatible and possess the capacity to grow. Defective heart valves replacement by surgery is now common, this improves the value and survival of life for a lot of patients. The recent paediatric heart valve implant is suboptimal due to their inability of somatic growth. They usually have multiple surgeries to change outgrown valves. Short‐lived valve bio‐prostheses occurring in older patients and younger ones who more usually need the replacement of its damaged heart with prosthesis led to a new invasive surgical interventions with an improved quality of life. The authors propose that nanofibre scaffold for paediatric tissue‐engineered heart valve will meet most of these conditions, most particularly those related to somatic growth, and, as the nanofibre scaffold is eroded, new valve is produced, the valve matures in the child until adulthood.
- 24 March 2017
- Published by Institution of Engineering and Technology (IET) in IET Nanobiotechnology
- Vol. 11 (5) , 493-500
Paediatric nanofibrous bioprosthetic heart valve
The search for an optimal aortic valve implant with durability, calcification resistance, excellent haemodynamic parameters and ability to withstand mechanical loading is yet to be met. Thus, there has been struggled to fabricate bio‐prosthetics heart valve using bioengineering. The consequential product must be resilient with suitable mechanical features, biocompatible and possess the capacity to grow. Defective heart valves replacement by surgery is now common, this improves the value and survival of life for a lot of patients. The recent paediatric heart valve implant is suboptimal due to their inability of somatic growth. They usually have multiple surgeries to change outgrown valves. Short‐lived valve bio‐prostheses occurring in older patients and younger ones who more usually need the replacement of its damaged heart with prosthesis led to a new invasive surgical interventions with an improved quality of life. The authors propose that nanofibre scaffold for paediatric tissue‐engineered heart valve will meet most of these conditions, most particularly those related to somatic growth, and, as the nanofibre scaffold is eroded, new valve is produced, the valve matures in the child until adulthood.
- 8 March 2017
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 45 (6) , 1051-1057
Recent advances in magnetoliposome for heart drug delivery
Magnetic nanoparticles (NPs) also have been subject of interest to the therapeutic and imaging field because of their unique magnetic properties. Magnetoliposomes (MLs) are made up of a combination of liposomes and magnetic NPs, and they have been proven to be a potential biomaterial to fields like magnetic-targeted drug delivery, MRI, etc. The efficiency of a drug delivery system to the heart determines the treatment strategy for most of the heart diseases. In this review article, we summarize the recent development and updates in the application of MLs as a drug delivery system for heart/cardiac diseases.
- 8 March 2017
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 45 (6) , 1051-1057
Recent advances in magnetoliposome for heart drug delivery
Magnetic nanoparticles (NPs) also have been subject of interest to the therapeutic and imaging field because of their unique magnetic properties. Magnetoliposomes (MLs) are made up of a combination of liposomes and magnetic NPs, and they have been proven to be a potential biomaterial to fields like magnetic-targeted drug delivery, MRI, etc. The efficiency of a drug delivery system to the heart determines the treatment strategy for most of the heart diseases. In this review article, we summarize the recent development and updates in the application of MLs as a drug delivery system for heart/cardiac diseases.
- Top Cited Papers
- 1 March 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 87, 209-222
Synthesis, properties and biomedical applications of carbon-based quantum dots: An updated review
- 1 March 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 87, 209-222
Top Cited PapersSynthesis, properties and biomedical applications of carbon-based quantum dots: An updated review
- 1 March 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 87, 321-331
A brief review on the application of nanoparticle enclosed herbal medicine for the treatment of infective endocarditis
- 1 March 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 87, 321-331
A brief review on the application of nanoparticle enclosed herbal medicine for the treatment of infective endocarditis
- 1 February 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 86, 316-323
Heart targeted nanoliposomal/nanoparticles drug delivery: An updated review
- 1 February 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 86, 316-323
Heart targeted nanoliposomal/nanoparticles drug delivery: An updated review
- 1 February 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 86, 221-231
Role of protease and protease inhibitors in cancer pathogenesis and treatment
- 1 February 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 86, 221-231
Role of protease and protease inhibitors in cancer pathogenesis and treatment
- 31 January 2017
- Published by Taylor & Francis in Journal of Cosmetic and Laser Therapy
- Vol. 19 (3) , 181-187
Clinical efficacy of liposome-encapsulatedAloe veraon melasma treatment during pregnancy
Background: Melasma is a challenging dermatological condition during pregnancy. The aim of this study was to determine the clinical efficacy of a topical liposome-encapsulated Aloe vera preparation, on melasma in pregnant women. In order to enhance the bioavailability of Aloe vera leaf gel extract (AGE), liposomes encapsulating Aloe vera were prepared and examined for their biochemical properties. Methods: In this double-blinded, randomized clinical trial, two groups of pregnant women with melasma who were at their second trimester of pregnancy or later were studied. The patients in the experimental group (90) received liposome-encapsulated AGE (in the form of gel), the other 90 patients were placed in the control group (AGE) for 5 weeks. The liposomes were prepared from a soybean lecithin (SLP-WHITE, 1.0 wt 15 %), with a high trapping efficiency for incorporating about 0.5 wt% AGE concentration. The stable liposomes were then prepared from 1.0 wt% of SLP-WHITE, and different concentrations of AGE were prepared by mechanochemical method using a microfluidizer and homogenizer. The liposomes obtained from 0.25 wt% of AGE were confirmed to be small unilamellar vesicles with a diameter < 200 nm, which remained well dispersed for at least 2 weeks. Our results are expressed as mean (±SD), the Melasma Area Severity Index (MASI) score was used to record melasma severity, and analysis of co-variance (ANCOVA) was used for data analysis. Results: After 5 weeks of melasma treatment in pregnant women, there was 32% improvement in the MASI score in the liposomal-AGE treatment group as compared to 10% improvement in the control group. The prevalence of melisma decreases with an increase in parity, i.e. 39 (43.35%), 34 (37.8%), 15 (16.7%) and 2 (2.2%) for the experimental groups, and 45 (50%), 35 (38.9%), 10 (11.1%) and 0 (0%) for the control group (p = 0.32). There was a significant difference between experimental and control groups in terms of mean MASI score after the trial. There was no significant difference between the groups regarding family history of melasma, occupation, frequency of sunscreen usage and hours of sun exposure. However, within each group, there was a slight to great significant difference observed. Conclusion: Liposome-encapsulated Aloe vera gel extract was superior to AGE in decreasing the severity of melasma in pregnancy due to their ease in percolation; it lightens the melasma, with only mild side effects.
- 31 January 2017
- Published by Taylor & Francis in Journal of Cosmetic and Laser Therapy
- Vol. 19 (3) , 181-187
Clinical efficacy of liposome-encapsulatedAloe veraon melasma treatment during pregnancy
Background: Melasma is a challenging dermatological condition during pregnancy. The aim of this study was to determine the clinical efficacy of a topical liposome-encapsulated Aloe vera preparation, on melasma in pregnant women. In order to enhance the bioavailability of Aloe vera leaf gel extract (AGE), liposomes encapsulating Aloe vera were prepared and examined for their biochemical properties. Methods: In this double-blinded, randomized clinical trial, two groups of pregnant women with melasma who were at their second trimester of pregnancy or later were studied. The patients in the experimental group (90) received liposome-encapsulated AGE (in the form of gel), the other 90 patients were placed in the control group (AGE) for 5 weeks. The liposomes were prepared from a soybean lecithin (SLP-WHITE, 1.0 wt 15 %), with a high trapping efficiency for incorporating about 0.5 wt% AGE concentration. The stable liposomes were then prepared from 1.0 wt% of SLP-WHITE, and different concentrations of AGE were prepared by mechanochemical method using a microfluidizer and homogenizer. The liposomes obtained from 0.25 wt% of AGE were confirmed to be small unilamellar vesicles with a diameter < 200 nm, which remained well dispersed for at least 2 weeks. Our results are expressed as mean (±SD), the Melasma Area Severity Index (MASI) score was used to record melasma severity, and analysis of co-variance (ANCOVA) was used for data analysis. Results: After 5 weeks of melasma treatment in pregnant women, there was 32% improvement in the MASI score in the liposomal-AGE treatment group as compared to 10% improvement in the control group. The prevalence of melisma decreases with an increase in parity, i.e. 39 (43.35%), 34 (37.8%), 15 (16.7%) and 2 (2.2%) for the experimental groups, and 45 (50%), 35 (38.9%), 10 (11.1%) and 0 (0%) for the control group (p = 0.32). There was a significant difference between experimental and control groups in terms of mean MASI score after the trial. There was no significant difference between the groups regarding family history of melasma, occupation, frequency of sunscreen usage and hours of sun exposure. However, within each group, there was a slight to great significant difference observed. Conclusion: Liposome-encapsulated Aloe vera gel extract was superior to AGE in decreasing the severity of melasma in pregnancy due to their ease in percolation; it lightens the melasma, with only mild side effects.
- 7 December 2016
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 45 (4) , 731-739
Cardioprotective effects of curcumin-loaded magnetic hydrogel nanocomposite (nanocurcumin) against doxorubicin-induced cardiac toxicity in rat cardiomyocyte cell lines
Curcumin, is a yellow substance extracted from Curcuma longa rhizomes, it is a crystalline compound that has been traditionally applied in culinary practices and medicines in India. The aim of our study is to demonstrate the efficacy of curcumin-loaded magnetic hydrogel nanocomposite in the treatment of heart hypertrophy. 10 rats weighing 150–200 g each were induced with heart failure using 2.5 mg/kg doxorubicin for 2 weeks. The test groups were treated with curcumin-loaded magnetic hydrogel nanocomposite while the control was treated with curcumin alone. malondialdehyde (MDA) levels, superoxide dismutase (SOD), and glutathione peroxidase (GPX) enzymes activities were monitored after two weeks of last the dose. In addition, the expression of three heart failure markers; atrial natriuretic peptide (ANP), B type natriuretic peptide (BNP), and beta major histocompatibility complex (β-MHC) were observed, it was found that the expression of these markers decreases with an increase in the concentration of curcumin (P < 0.05). Curcumin elevated the decreased level of GPX and SOD, and reduced the elevated level of MDA in cardiac tissue. We suggest this combination to be a potent therapy for heart failure and hypertension in the nearest future.
- 7 December 2016
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 45 (4) , 731-739
Cardioprotective effects of curcumin-loaded magnetic hydrogel nanocomposite (nanocurcumin) against doxorubicin-induced cardiac toxicity in rat cardiomyocyte cell lines
Curcumin, is a yellow substance extracted from Curcuma longa rhizomes, it is a crystalline compound that has been traditionally applied in culinary practices and medicines in India. The aim of our study is to demonstrate the efficacy of curcumin-loaded magnetic hydrogel nanocomposite in the treatment of heart hypertrophy. 10 rats weighing 150–200 g each were induced with heart failure using 2.5 mg/kg doxorubicin for 2 weeks. The test groups were treated with curcumin-loaded magnetic hydrogel nanocomposite while the control was treated with curcumin alone. malondialdehyde (MDA) levels, superoxide dismutase (SOD), and glutathione peroxidase (GPX) enzymes activities were monitored after two weeks of last the dose. In addition, the expression of three heart failure markers; atrial natriuretic peptide (ANP), B type natriuretic peptide (BNP), and beta major histocompatibility complex (β-MHC) were observed, it was found that the expression of these markers decreases with an increase in the concentration of curcumin (P < 0.05). Curcumin elevated the decreased level of GPX and SOD, and reduced the elevated level of MDA in cardiac tissue. We suggest this combination to be a potent therapy for heart failure and hypertension in the nearest future.